Historically, optic nerve involvement has been excluded from MS diagnostic criteria, but its inclusion in the new iteration ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Hims & Hers Health Inc. shares slid over 2.8% on Tuesday and continued declining after-hours trading after Eli Lilly ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery’s Substack. In this article, we will ...

Hims & Hers has been expanding its presence in the weight management market, with its existing Novo partnership representing ...

Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...